ArticleNPJ Parkinson's disease2024
Diagnostic utility of 7T neuromelanin imaging of the substantia nigra in Parkinson's disease.
Article in NPJ Parkinson's disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Utility of Baseline Pathological, Neuroimaging and Clinical Markers for Prognosis in Early Parkinson's Disease.Journal of geriatric psychiatry and neurology · 2026Article
- Preparing for Parkinson's disease prevention trials: Current progress and future directions.Journal of Parkinson's disease · 2026Review
- Neuroimaging of the monoaminergic system in Parkinson's disease: A narrative review.Neuroimage. Reports · 2026Review
- Superior dorsal nigral hyperintensity depiction at 7 T MRI using CLEAR-DESS improves diagnosis performance of Parkinson's disease.NPJ Parkinson's disease · 2026Article
- Associations of neuromelanin in the substantia nigra with antipsychotic response in schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- The quest for the best: manual, atlas- and spatial prior-based delineation of locus coeruleus.NeuroImage. Clinical · 2026Article
- Imaging biomarkers in neurodegenerative diseases: advances and challenges.Frontiers in aging neuroscience · 2026Review
- From dysbiosis to dysfunction: specific gut microbes and metabolites in the pathogenesis of Parkinson's disease.Sustainable microbiology · 2026Review
- Limited predictive value of preoperative nigrosome integrity for motor outcomes in Parkinson's disease deep brain stimulation.NPJ Parkinson's disease · 2025Article
- Uncovering the neurological substrates underlying restlessness in cluster headache - A functional MRI study.The journal of headache and pain · 2025Article
- Dorsal hyperintensity and iron deposition patterns in the substantia nigra of Parkinson's disease, idiopathic REM sleep behavior disorder, and Parkinson-plus syndromes at 7T MRI: a prospective diagnostic study.Translational neurodegeneration · 2025Article
- Application of Deep Learning Accelerated Image Reconstruction in T2-Weighted Turbo Spin-Echo Imaging of the Brain at 7T.AJNR. American journal of neuroradiology · 2025Article
- Spatial variations and precise location of substantia nigra hyperechogenicity in Parkinson's disease using TCS-MR fusion imaging.NPJ Parkinson's disease · 2025Article
- Clinical 7 Tesla magnetic resonance imaging: Impact and patient value in neurological disorders.Journal of internal medicine · 2025Review
- Advanced Magnetic Resonance Imaging for Early Diagnosis and Monitoring of Movement Disorders.Brain sciences · 2025Review
- Deep-learning segmentation of the substantia nigra from multiparametric MRI: Application to Parkinson's disease.Imaging neuroscience (Cambridge, Mass.) · 2025Article
- Neuromelanin-sensitive MRI for mechanistic research and biomarker development in psychiatry.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Review
- Ultra-high-field 7-Tesla magnetic resonance imaging in fragile X tremor/ataxia syndrome (FXTAS).The neuroradiology journal · 2024Article
- Multispectral 7 Tesla MRI as a potential predictor of dopamine transporter deficiency in Parkinson's disease.Imaging neuroscience (Cambridge, Mass.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a prevalent neurodegenerative disorder that presents a diagnostic challenge due to symptom overlap with other disorders. Neuromelanin (NM) imaging is a promising biomarker for PD, but adoption has been limited, in part due to subpar performance at standard MRI field strengths. We aimed to evaluate the diagnostic utility of ultra-high field 7T NM-sensitive imaging in the diagnosis of PD versus controls and essential tremor (ET), as well as NM differences among PD subtypes. A retrospective case-control study was conducted including PD patients, ET patients, and controls. 7T NM-sensitive 3D-GRE was acquired, and substantia nigra pars compacta (SNpc) volumes, contrast ratios, and asymmetry indices were calculated. Statistical analyses, including general linear models and ROC curves, were employed. Twenty-one PD patients, 13 ET patients, and 18 controls were assessed. PD patients exhibited significantly lower SNpc volumes compared to non-PD subjects. SNpc total volume showed 100% sensitivity and 96.8% specificity (AUC = 0.998) for differentiating PD from non-PD and 100% sensitivity and 95.2% specificity (AUC = 0.996) in differentiating PD from ET. Contrast ratio was not significantly different between PD and non-PD groups (p = 0.07). There was also significantly higher asymmetry index in SNpc volume in PD compared to non-PD cohorts (p < 0.001). NM signal loss in PD predominantly involved the inferior, posterior, and lateral aspects of SNpc. Akinetic-rigid subtype showed more significant NM signal loss compared to tremor dominant subtype (p < 0.001). 7T NM imaging demonstrates potential as a diagnostic tool for PD, including potential distinction between subtypes, allowing improved understanding of disease progression and subtype-related characteristics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.